These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 15509501)

  • 1. Targeted expression of insulin-like growth factor-I reduces early myofiber necrosis in dystrophic mdx mice.
    Shavlakadze T; White J; Hoh JF; Rosenthal N; Grounds MD
    Mol Ther; 2004 Nov; 10(5):829-43. PubMed ID: 15509501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic administration of IGF-I enhances oxidative status and reduces contraction-induced injury in skeletal muscles of mdx dystrophic mice.
    Schertzer JD; Ryall JG; Lynch GS
    Am J Physiol Endocrinol Metab; 2006 Sep; 291(3):E499-505. PubMed ID: 16621899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stimulation of calcineurin signaling attenuates the dystrophic pathology in mdx mice.
    Chakkalakal JV; Harrison MA; Carbonetto S; Chin E; Michel RN; Jasmin BJ
    Hum Mol Genet; 2004 Feb; 13(4):379-88. PubMed ID: 14681302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AAV vector-mediated microdystrophin expression in a relatively small percentage of mdx myofibers improved the mdx phenotype.
    Yoshimura M; Sakamoto M; Ikemoto M; Mochizuki Y; Yuasa K; Miyagoe-Suzuki Y; Takeda S
    Mol Ther; 2004 Nov; 10(5):821-8. PubMed ID: 15509500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disodium cromoglycate protects dystrophin-deficient muscle fibers from leakiness.
    Marques MJ; Ventura Machado R; Minatel E; Santo Neto H
    Muscle Nerve; 2008 Jan; 37(1):61-7. PubMed ID: 17724738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phenotypic improvement of dystrophic muscles by rAAV/microdystrophin vectors is augmented by Igf1 codelivery.
    Abmayr S; Gregorevic P; Allen JM; Chamberlain JS
    Mol Ther; 2005 Sep; 12(3):441-50. PubMed ID: 16099410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-TNFalpha (Remicade) therapy protects dystrophic skeletal muscle from necrosis.
    Grounds MD; Torrisi J
    FASEB J; 2004 Apr; 18(6):676-82. PubMed ID: 15054089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological activation of PPARbeta/delta stimulates utrophin A expression in skeletal muscle fibers and restores sarcolemmal integrity in mature mdx mice.
    Miura P; Chakkalakal JV; Boudreault L; Bélanger G; Hébert RL; Renaud JM; Jasmin BJ
    Hum Mol Genet; 2009 Dec; 18(23):4640-9. PubMed ID: 19744959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted inhibition of Ca2+ /calmodulin signaling exacerbates the dystrophic phenotype in mdx mouse muscle.
    Chakkalakal JV; Michel SA; Chin ER; Michel RN; Jasmin BJ
    Hum Mol Genet; 2006 May; 15(9):1423-35. PubMed ID: 16551657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intrinsic laryngeal muscles are spared from myonecrosis in the mdx mouse model of Duchenne muscular dystrophy.
    Marques MJ; Ferretti R; Vomero VU; Minatel E; Neto HS
    Muscle Nerve; 2007 Mar; 35(3):349-53. PubMed ID: 17143878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A highly functional mini-dystrophin/GFP fusion gene for cell and gene therapy studies of Duchenne muscular dystrophy.
    Li S; Kimura E; Ng R; Fall BM; Meuse L; Reyes M; Faulkner JA; Chamberlain JS
    Hum Mol Genet; 2006 May; 15(10):1610-22. PubMed ID: 16595609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A canine minidystrophin is functional and therapeutic in mdx mice.
    Wang B; Li J; Qiao C; Chen C; Hu P; Zhu X; Zhou L; Bogan J; Kornegay J; Xiao X
    Gene Ther; 2008 Aug; 15(15):1099-106. PubMed ID: 18432277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Branched fibres in old dystrophic mdx muscle are associated with mechanical weakening of the sarcolemma, abnormal Ca2+ transients and a breakdown of Ca2+ homeostasis during fatigue.
    Head SI
    Exp Physiol; 2010 May; 95(5):641-56. PubMed ID: 20139167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of a NOS transgene in dystrophin-deficient muscle reduces muscle membrane damage without increasing the expression of membrane-associated cytoskeletal proteins.
    Tidball JG; Wehling-Henricks M
    Mol Genet Metab; 2004 Aug; 82(4):312-20. PubMed ID: 15308129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Temporal gene expression profiling of dystrophin-deficient (mdx) mouse diaphragm identifies conserved and muscle group-specific mechanisms in the pathogenesis of muscular dystrophy.
    Porter JD; Merriam AP; Leahy P; Gong B; Feuerman J; Cheng G; Khanna S
    Hum Mol Genet; 2004 Feb; 13(3):257-69. PubMed ID: 14681298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced necrosis of dystrophic muscle by depletion of host neutrophils, or blocking TNFalpha function with Etanercept in mdx mice.
    Hodgetts S; Radley H; Davies M; Grounds MD
    Neuromuscul Disord; 2006 Oct; 16(9-10):591-602. PubMed ID: 16935507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Restoration of all dystrophin protein interactions by functional domains in trans does not rescue dystrophy.
    Gardner KL; Kearney JA; Edwards JD; Rafael-Fortney JA
    Gene Ther; 2006 May; 13(9):744-51. PubMed ID: 16307000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Adeno-associated virus vector carrying human minidystrophin gene SMCKA3999 effectively ameliorates dystrophic pathology in mdx model mice].
    Li HH; Zhang SM; Fang SY; Chen CL; Luo YD; Guan Y; Wang DW; Xiao X
    Zhonghua Yi Xue Za Zhi; 2003 Sep; 83(17):1513-6. PubMed ID: 14521733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Local and distant transfection of mdx muscle fibers with dystrophin and LacZ genes delivered in vivo by synthetic microspheres.
    Baranov A; Glazkov P; Kiselev A; Ostapenko O; Mikhailov V; Ivaschenko T; Sabetsky V; Baranov V
    Gene Ther; 1999 Aug; 6(8):1406-14. PubMed ID: 10467365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced dystrophic progression in mdx mice by exercise and beneficial effects of taurine and insulin-like growth factor-1.
    De Luca A; Pierno S; Liantonio A; Cetrone M; Camerino C; Fraysse B; Mirabella M; Servidei S; Rüegg UT; Conte Camerino D
    J Pharmacol Exp Ther; 2003 Jan; 304(1):453-63. PubMed ID: 12490622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.